These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6821398)

  • 1. Clinicopharmacological study of long-term Jumex + Dopaflex combination treatment in Parkinson's syndrome.
    Antóny M; Tóth G; Széplaki Z
    Ther Hung; 1982; 30(4):168-71. PubMed ID: 6821398
    [No Abstract]   [Full Text] [Related]  

  • 2. Observations made with L-deprenil (Jumex) in the long-term treatment of outpatients with Parkinson's syndrome.
    Gyimóti G; Csanaky A; Leposa D
    Ther Hung; 1983; 31(1):26-30. PubMed ID: 6443750
    [No Abstract]   [Full Text] [Related]  

  • 3. [Slowing the progression of Parkinson syndrome by early administration of deprenyl].
    Baas H; Fischer PA
    Nervenarzt; 1990 Feb; 61(2):127-9. PubMed ID: 2108395
    [No Abstract]   [Full Text] [Related]  

  • 4. Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease.
    Birkmayer W; Riederer P
    Adv Neurol; 1984; 40():475-81. PubMed ID: 6421111
    [No Abstract]   [Full Text] [Related]  

  • 5. [Deprenyl as a co-adjuvant in the treatment of Parkinson disease].
    Ferrari E; Cacudi N; de Mari M; Iliceto G; Lamberti P
    Acta Neurol (Napoli); 1986 Aug; 8(4):455-61. PubMed ID: 3096087
    [No Abstract]   [Full Text] [Related]  

  • 6. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MPTP: clinical implications.
    Stern G
    J Neural Transm Suppl; 1986; 20():77-81. PubMed ID: 3091763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 9. Protective effect of selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208
    [No Abstract]   [Full Text] [Related]  

  • 10. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y; Kondo T; Takubo H; Yokochi F
    No To Shinkei; 1996 May; 48(5):467-72. PubMed ID: 8672306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Parkinson's disease.
    Bergus G
    J Fam Pract; 1996 May; 42(5):457-8. PubMed ID: 8642360
    [No Abstract]   [Full Text] [Related]  

  • 12. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
    Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
    [No Abstract]   [Full Text] [Related]  

  • 14. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y; Kondo T; Takubo H; Yokochi F
    No To Shinkei; 1994 May; 46(5):465-71. PubMed ID: 8060685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
    Stryjer R; Klein C; Treves TA; Rabey JM
    Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selegiline and mortality in Parkinson's disease.
    Olanow CW; Fahn S; Langston JW; Godbold J
    Ann Neurol; 1996 Dec; 40(6):841-5. PubMed ID: 9007088
    [No Abstract]   [Full Text] [Related]  

  • 18. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome.
    Trebini F; Daniele D; Gillio S; Scarzella L
    Acta Neurol (Napoli); 1985 Oct; 7(5):432-9. PubMed ID: 3933283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.